PCAS: Change of shareholder at Seqens

Ecully, December 16, 2021



Seqens announced on December 16, 2021 that the funds advised by SK Capital have become majority shareholders of the Group Рalongside BPI France, Nov Sant̩ Actions Non Cot̩es, M̩rieux Equity Partners, Ardian, Eximium and the general management of Seqens.

Along with this investment, Seqens partnered with Wavelength Pharmaceuticals, an API maker and a CDMO group company, an existing SK Capital portfolio company. Seqens also sold its non-strategic mineral specialties activities

By decision of December 10, 2021, in application of the general regulations of the Autorité des marchés financiers – article 234-9-8 °, the Autorité des marchés financiers granted an exemption from the obligation to file a draft public offer. repurchase of shares PCAS after consulting the investment funds by SK Capital has acquired a majority stake in the Seqens group.

In addition, Mr. Pierre Luzeau has held the position of Chief Executive Officer since the Board of Directors meeting of March 23, 2020 – which decided to temporarily combine the functions of Mr. Pierre Luzeau as Chairman and Chief Executive Officer.

The Board of Directors of December 16, 2021 took note of the resignation of Mr. Pierre Luzeau from his duties as Chief Executive Officer. The Board of Directors is pleased that Mr. Pierre Luzeau has accepted to remain Chairman of the Board of Directors and that the Company has continued to benefit from his successful experience in both functions and from his attachment to the Group.

The Board of Directors, which met on December 16, also appointed Mr. Philippe Clavel as Chief Executive Officer for an indefinite period. Mr. Philippe Clavel will thus support the PCAS teams in the continued deployment of the transformation plans necessary for modernization but also for making operations more reliable, while developing new technological expertise.

Mr. Philippe Clavel spent an important part of his career within the Sanofi group, where he managed the Active Ingredient Solution activity. He has significant knowledge of the API and CDMO market, and he will be able to support PCAS teams in the face of future challenges, thanks to his experience, commitment and expertise.

Mr. Philippe Clavel will be remunerated in accordance with the remuneration policy detailed in the corporate governance report of the Board of Directors, which was presented to the General Meeting on June 9, 2021.


PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With around 10% of turnover dedicated to R&D and a strong international presence, PCAS is the privileged industrial partner of the major global groups leaders. Benefiting from particularly high standards, the company offers a growing range of products and proprietary solutions in cutting-edge segments. PCAS achieved sales of 194.1 million euros in 2020 and employs nearly 1,100 people in six countries.

To find out more about PCAS: www.pcas.com


Pierre Luzeau / Eric Moissenot

Emmanuel Huynh / Louis-Victor Delouvrier
Financial Communication and Investor Relations

Phone. : +33 1 69 79 60 00
Phone. : +33 1 44 71 98 53
[email protected]
  • PCAS_CP_CA December 16, 2021 – VF -UK

Comments are closed.